HER2-mutant Non-Small Cell Lung Cancer Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)

DelveInsight's, "HER2-mutant Non-Small Cell Lung Cancer Pipeline Insight 2023" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in the HER2-mutant Non-Small Cell Lung Cancer pipeline landscape. It covers the HER2-mutant Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2-mutant Non-Small Cell Lung Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the HER2-mutant Non-Small Cell Lung Cancer Pipeline Report

*DelveInsight's HER2-mutant Non-Small Cell Lung Cancer pipeline report depicts a robust space with 5+ active players working to develop 5+ pipeline therapies for HER2-mutant Non-Small Cell Lung Cancer treatment. *The leading companies working in the HER2-mutant Non-Small Cell Lung Cancer Market include Dizal Pharmaceuticals, Puma Biotechnology, AstraZeneca, Jiangsu Hengrui Medicine, Spectrum Pharmaceuticals Inc. and others. *Promising HER2-mutant Non-Small Cell Lung Cancer Pipeline Therapies in the various stages of development include Trastuzumab deruxtecan, ELVN-002, Trastuzumab emtansine, Neratinib, Temsirolimus, DZD9008, and others. *November 2023: AstraZeneca announced a study of Phase 2 clinical trials for Trastuzumab deruxtecan. The purpose of this study is to evaluate the efficacy and safety of T-DXd in participants with HER2 mutant metastatic non-squamous NSCLC. *November 2023: Enliven Therapeutics announced a study of Phase 1 clinical trials for ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki and Trastuzumab emtansine. The goal of this clinical trial is to test ELVN-002 in people with cancers that have an abnormal HER2 gene. The main question the trial aims to answer is if ELVN-002 is safe and tolerable at different doses. A second main question is to evaluate the concentration of ELVN-002 in the blood at different doses and to see how this correlates with safety and see how the concentration of drug changes over time. The third main question is to see if ELVN-002 works to shrink cancers that have HER2 genetic abnormalities, particularly non-small cell lung cancer. *October 2023: M.D. Anderson Cancer Center announced a study of Phase 2 clinical trials for Poziotinib. This phase II trial studies how well poziotinib works in treating patients with non-small lung cancer with an EGFR or HER2 exon 20 mutation that is stage IV or has come back (recurrent). Poziotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Request a sample and discover the recent advances in HER2-mutant Non-Small Cell Lung Cancer Treatment Drugs @ HER2-mutant Non-Small Cell Lung Cancer Pipeline Report

In the HER2-mutant Non-Small Cell Lung Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, HER2-mutant Non-Small Cell Lung Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

HER2-mutant Non-Small Cell Lung Cancer Overview

Lung cancer is the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) accounts for more than 80% of all lung cancers. NSCLC is one of the most genomically diverse cancers, making it very difficult to treat. For all NSCLC patients who have the adenocarcinoma subtype, testing for alterations in epidermal growth factor receptor (EGFR), mesenchymal epithelial transition factor (MET), b-raf proto-oncogene (BRAF), anaplastic lymphoma kinase (ALK), ROS proto-oncogene 1 (ROS1), ret proto-oncogene (RET) and neurotrophic tyrosine receptor kinase (NTRK) is recommended by the National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) guidelines.

Find out more about HER2-mutant Non-Small Cell Lung Cancer Therapeutics Assessment @ HER2-mutant Non-Small Cell Lung Cancer Preclinical and Discovery Stage Products

HER2-mutant Non-Small Cell Lung Cancer Emerging Drugs Profile

*DZD-9008: Dizal Pharmaceuticals *Enhertu: AstraZeneca *Pyrotinib: Jiangsu Hengrui Medicine

HER2-mutant Non-Small Cell Lung Cancer Pipeline Therapeutics Assessment

There are approx. 5+ key companies which are developing the therapies for HER2-mutant Non-Small Cell Lung Cancer. The HER2-mutant Non-Small Cell Lung Cancer companies which have their HER2-mutant Non-Small Cell Lung Cancer drug candidates in the most advanced stage, i.e. Preregistration include, AstraZeneca.

DelveInsight's HER2-mutant Non-Small Cell Lung Cancer Pipeline Report covers around 5+ products under different phases of clinical development like

*Late stage products (Phase III) *Mid-stage products (Phase II) *Early-stage product (Phase I) along with the details of *Pre-clinical and Discovery stage candidates *Discontinued & Inactive candidates

HER2-mutant Non-Small Cell Lung Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

*Intra-articular *Intraocular *Intrathecal *Intravenous *Ophthalmic *Oral *Parenteral *Subcutaneous *Topical *Transdermal

HER2-mutant Non-Small Cell Lung Cancer Pipeline Products have been categorized under various Molecule types such as

*Oligonucleotide *Peptide *Small molecule

Learn more about the emerging HER2-mutant Non-Small Cell Lung Cancer Pipeline Therapies @ HER2-mutant Non-Small Cell Lung Cancer Clinical Trials Assessment

Scope of the HER2-mutant Non-Small Cell Lung Cancer Pipeline Report

*Coverage- Global *HER2-mutant Non-Small Cell Lung Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination *HER2-mutant Non-Small Cell Lung Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III *HER2-mutant Non-Small Cell Lung Cancer Companies- Dizal Pharmaceuticals, Puma Biotechnology, AstraZeneca, Jiangsu Hengrui Medicine, Spectrum Pharmaceuticals Inc. and others. *HER2-mutant Non-Small Cell Lung Cancer Pipeline Therapies- Trastuzumab deruxtecan, ELVN-002, Trastuzumab emtansine, Neratinib, Temsirolimus, DZD9008, and others.

Dive deep into rich insights for new drugs for HER2-mutant Non-Small Cell Lung Cancer Treatment, Visit @ HER2-mutant Non-Small Cell Lung Cancer Market Drivers and Barriers, and Future Perspective

Table of Content

*Introduction *Executive Summary *HER2-mutant Non-Small Cell Lung Cancer: Overview *Pipeline Therapeutics *Therapeutic Assessment *HER2-mutant Non-Small Cell Lung Cancer- DelveInsight's Analytical Perspective *Late Stage Products (Preregistration) *Enhertu: AstraZeneca *Drug profiles in the detailed report..... *Mid Stage Products (Phase II) *DZD-9008: Dizal Pharmaceuticals *Drug profiles in the detailed report..... *Early Stage Products (Phase I) *Drug name : Company name *Drug profiles in the detailed report..... *Preclinical and Discovery Stage Products *Drug name : Company name *Drug profiles in the detailed report..... *Inactive Products *HER2-mutant Non-Small Cell Lung Cancer Key Companies *HER2-mutant Non-Small Cell Lung Cancer Key Products *HER2-mutant Non-Small Cell Lung Cancer- Unmet Needs *HER2-mutant Non-Small Cell Lung Cancer- Market Drivers and Barriers *HER2-mutant Non-Small Cell Lung Cancer- Future Perspectives and Conclusion *HER2-mutant Non-Small Cell Lung Cancer Analyst Views *HER2-mutant Non-Small Cell Lung Cancer Key Companies *Appendix

For further information on the HER2-mutant Non-Small Cell Lung Cancer Pipeline therapeutics, reach out to HER2-mutant Non-Small Cell Lung Cancer Unmet Needs and Analyst Views

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact

Company Name: DelveInsight Business Research LLP

Contact Person: Yash Bhardwaj

Email: [e-mail]

Phone: [phone]

Address:304 S. Jones Blvd #2432

City: Las Vegas

State: NV

Country: United States

Website: https://www.delveinsight.com/report-store/major-depressive-disorder-market

Source: www.abnewswire.com

.

(C) 2023 M2 COMMUNICATIONS, source M2 PressWIRE